Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer
GN Hortobagyi - Seminars in oncology, 2001 - Elsevier
HER2/neu amplification/overexpression confers more aggressive and malignant
characteristics on breast cancer cells. Patients with HER2/neu-amplified breast cancer have
a worse prognosis than those with normal HER2/neu expression. Over the past decade, the
intracellular signaling pathways associated with this growth factor receptor have been
elucidated. Multiple therapeutic strategies that target the HER2/neu oncoprotein are under
development. Trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA), a …
characteristics on breast cancer cells. Patients with HER2/neu-amplified breast cancer have
a worse prognosis than those with normal HER2/neu expression. Over the past decade, the
intracellular signaling pathways associated with this growth factor receptor have been
elucidated. Multiple therapeutic strategies that target the HER2/neu oncoprotein are under
development. Trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA), a …
